Literatur
-
1
Attal M, Harousseau J L, Stoppa A M. et al. Intergroupe Francais Du Myelome .
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.
N Engl J Med.
1996;
335
91-97
-
2
Barille-Nion S, Barlogie B, Bataille R. et al .
Advances in Biology and Therapy of Multiple Myeloma. Hematology.
Am Soc Hematol Educ Program.
2003;
1
248-278
-
3
Bjorkstrand B, Svensson H, Goldschmidt H. et al .
Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
Bone Marrow Transplant.
2001;
27
511-515
-
4
Child J A, Morgan G J, Davies F E. et al .
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
N Engl J Med.
2003;
348
1875-1883
-
5
Cunningham D, Powles R, Malpas J. et al .
A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.
Br J Haematol.
1998;
102
495-502
-
6
Fritz E, Ludwig H.
Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.
Ann Oncol.
2000;
11
1427-1436
-
7
Gahrton G, Svensson H, Cavo M. et al .
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation Centres.
Br J Haematol.
2001;
113
209-216
-
8
Kropff M H, Lang N, Bisping G. et al .
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Br J Haematol.
2003;
122
607-616
-
9
Moreau P, Facon T, Attal M. et al .
Comparison of 200 mg/m[2) melphalan and 8 Gy total body irradiation plus 140 mg/m[2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial.
Blood.
2002;
99
731-735
-
10
Myeloma Trialists’ Collaborative Group .
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.
J Clin Oncol.
1998;
16
3832-3842
-
11
Myeloma Trialists’ Collaborative Group .
Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.
Br J Haematol.
2001;
113
1020-1034
-
12
Palumbo A, Triolo S, Argentino C. et al .
Dose-intensive melphalan with stem cell support (mel100) is superior to standard treatment in elderly myeloma patients.
Blood.
1999;
94
1248-1253
-
13
Richardson P G, Barlogie B, Berenson J. et al .
A phase 2 study of bortezomib in relapsed, refractory myeloma.
N Engl J Med.
2003;
348
2609-2617
-
14
Singhal S, Mehta J, Desikan R. et al .
Antitumor activity of thalidomide in refractory multiple myeloma.
N Engl J Med.
1999;
341
1565-1571
-
15
Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J.
Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.
Bone Marrow Transplant.
2002;
30
673-679
Dr. med. Wolfram Jung
Georg-August-Universität Göttingen, Zentrum Innere Medizin, Abteilung Hämatologie und Onkologie
Robert Koch-Straße 40
37075 Göttingen
Phone: 0551/398535
Fax: 0551/398587
Email: wolfram.jung@med.uni-goettingen.de
